CISSPECT DESK-LAB

The world's first fully automated synthesis module

22 July 2020

The automated DESK-LAB process:

Ensures a high quality reproduction of each radiopharmaceutical batch

Reduces and simplifies the handling of radioactive material by the radiochemistry lab scientists

Automated GMP synthesis at your desk!

CISSPECT DESK-LAB represents a great leap forward for the development of radiopharmaceuticals and personalised drug discovery. Recently, we have developed the world’s first fully automated synthesis module, CISSPECT DESK-LAB, for the synthesis of Pt-195m cisplatin and other platinum compounds

The module has been designed for the production of GMP Pt-195m Cisplatin to facilitate a human pilot study. We have achieved this in close collaboration with our industrial partner FutureChemistry and renowned Dutch Academic Medical Centres.

Why automated synthesis?

The synthesis of a radiopharmaceutical can be a difficult process, with a series of reactions before getting to the final product. In the case of CISSPECT, there is a total of 7 steps required, until the desired molecules have formed in order to be administered to patients. At each step, it is of great importance that exact amounts are added to Platinum intermediate compounds, for a complete reaction. By using specific techniques developed together with our partner, the 7 step process has been automated in the DESKLAB module, which ensures a high quality reproduction of each batch of the radiopharmaceutical under investigation. In addition, it reduces and simplifies the handling of radioactive materials by the radiochemistry lab scientists and within a Hot Cell with limited access.

Process steps in DESK-LAB

drag for more

DISSOLVE

REDUCE

IODINATE

AMINATE

HYDROLYSE

CHLORINATE

DISPENSE

Results

drag for more

Fully automated synthesis of Pt-195m cisplatin

For the GMP production of various Platinum compounds

Automated dispensing into patient doses

In addition to the Dhara synthesis according to Hoeschele et. al., Radiochimica Acta 1982

Partner: FutureChemistry

FutureChemistry Holding B.V. develops, builds and implements equipment and processes for manufacturing of chemicals with a high added value. With a focus in particular on two product groups: nanomaterials and radiopharmaceuticals.

  • Located at the Technology and Science Park of the Radboud University Nijmegen
  • Years of experience in flow chemistry

“A great leap forward for the development of radiopharmaceuticals and personalised drug discovery.“

CISSPECT = Pt-195m = radioactive cisplatin

The main draw backs of cisplatin chemotherapy treatment is kidney toxicity, as well as the low response rate in many cases, which cannot be predicted beforehand. Pt-195m cisplatin, or CISSPECT, is developed to enable quantification of the in vivo bio distribution of cisplatin, a standard chemotherapeutic agent. Pt-195m cisplatin may be able to select patients who will not respond to cisplatin chemotherapy, or those patients who will suffer from severe kidney toxicity due to cisplatin treatment.

CISSPECT® DESK-LAB - Automated GMP synthesis at your desk!

Human Pilot

The feasibility of SPECT imaging and quantification of Pt-195m in a preclinical setting has already been  shown (E.A. Aalbersberg et al., EJNMMI 2017 (44), 8, 1347 – 1354). As a next step, the feasibility in humans will be assessed. If successful, Pt-195m cisplatin contributes to optimising treatment outcome of chemo(radio)therapy and reducing toxicity in a personalised approach.

Relevant produts

  • High specific activity
  • Reliable synthesis
  • For human use
Read more
  • No additional transport required from the reactor
  • Produced in parallel with molybdenum-99
  • Low enrichted uranium based (LEU)
Read more